- Home
- / Maze Therapeutics
Maze Therapeutics
Maze Therapeutics Summary
Company Summary
- Overview
- Maze Therapeutics is a clinical-stage biopharmaceutical company. It develops small molecule precision medicines for patients with renal, cardiovascular, and related metabolic diseases.
- Type
- Public
- Status
- Active
- Founded
- 2018
- HQ
- South San Francisco, CA, US | view all locations
- Website
- https://www.mazetx.com/
- Cybersecurity rating
Table of Contents
Key People
Jason Coloma, Chief Executive Officer, President, Chief Mazer, Director
Brendan Bulik-Sullivan, Director
Jonathan Lim, Director
LocationsView all
3 locations detected
South San Francisco, CA HQ
United States
171 Oyster Point Blvd STE 300
Redwood City, CA
United States
123 Saginaw Dr
South San Francisco, CA
United States
131 Oyster Point Blvd #200
Maze Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $20.0M
- Gross profit (Q1, 2026)
- $18.2M
- Net income (Q1, 2026)
- ($24.2M)
- Cash (FY, 2025)
- $189.2M
- EBIT (Q1, 2026)
- ($26.6M)